Filter by:
Cardiovascular
March 2026
American College of Cardiology Scientific Session & Expo
Reduced cardiac stress and inflammatory proteomic signatures in obstructive and nonobstructive HCM following EDG-7500 treatment in CIRRUS-HCM
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Long-Term Stabilization of Function in Becker: Sevasemten Prevented Functional Decline Up to 3.5 Years with MESA Open-Label Extension
Muscular Dystrophy
March 2026
Industry Forum at the 2026 MDA Clinical and Scientific Conference
Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Female carriers of BMD and DMD mutations show elevated muscle injury proteins, and muscle loss progression is predicted by plasma ART3 concentration
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Effects of sevasemten on LVEF and NT-proBNP in adults with Becker muscular dystrophy in
Muscular Dystrophy
March 2026
2026 MDA Clinical and Scientific Conference
Patient-Focused Drug Development: Understanding the Patient Experience and Meaningful Treatment Outcomes in Becker Muscular Dystrophy via Qualitative Interviews
Cardiovascular
January 2026
Cardiometabolism in Health and Disease
Chronic EDG-7500 treatment prevents left atrial metabolic dysfunction in a Yucatan mini-pig model of genetic non-obstructive hypertrophic cardiomyopathy
Cardiovascular
December 2025
CVCT
CIRRUS-HCM: A Multiple-Dose Phase 2 Study of Safety, Tolerability, and Effects on Hemodynamics and Functional Capacity of the Novel Cardiac Sarcomere Modulator EDG-7500 in Hypertrophic Cardiomyopathy
Muscular Dystrophy
December 2025
European Medical Journal
